Can Recovery From Depression Be Achieved?
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Even though a variety of treatments are available for depression, many patients experience an incomplete response, resulting in chronic functional impairment. The authors present a therapeutic heuristic that derives, in part, from a body of research that suggests that symptoms of mood disorders can be separated into three distinct components: somatic anxiety, which is most prominent in anxiety disorders, such as panic; anhedonia or low positive affect, which is most specific to depression; and general distress, which is present with both anxiety and depressive disorders. General distress and somatic anxiety appear to be significantly modulated by serotonin, and serotonergic drugs may exert their effects most significantly on these symptoms. On the other hand, positive affect, the dimension of reward-oriented motivation and enjoyment, appears to be most dependent on dopamine and, indirectly, norepinephrine. Thus a theoretical heuristic can be derived on the basis of the predominance of residual symptoms. Serotonergic agents would be chosen for monotherapy or augmentation for symptoms of distress. Alternatively, catecholaminergic drugs would be the first choice for anhedonia and decreased motivation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications
Clark, L. A., & Watson, D. (1991) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.100.3.316 · Cited by 4,601
Lifetime Prevalence of Specific Psychiatric Disorders in Three Sites
Robins, L. N. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1984.01790210031005 · Cited by 2,550
Depue, R. A., & Collins, P. F. (1999) · Behavioral and Brain Sciences · doi:10.1017/s0140525x99002046 · Cited by 2,046
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959
Comorbidity of anxiety and unipolar mood disorders
Mineka, S., Watson, D., & Clark, L. A. (1998) · Annual Review of Psychology · doi:10.1146/annurev.psych.49.1.377 · Cited by 1,573
Brown, T. A., Chorpita, B. F., & Barlow, D. H. (1998) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.107.2.179 · Cited by 1,400
Fear and anxiety: Animal models and human cognitive psychophysiology
Lang, P. J., Davis, M., & Öhman, A. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00343-8 · Cited by 1,162
Emotion, motivation, and anxiety: brain mechanisms and psychophysiology
Lang, P. J., Bradley, M. M., & Cuthbert, B. N. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00275-3 · Cited by 1,043
Expression cloning of a cocaine-and antidepressant-sensitive human noradrenaline transporter
Pacholczyk, T., Blakely, R. D., & Amara, S. G. (1991) · Nature · doi:10.1038/350350a0 · Cited by 933
Role of locus coeruleus in attention and behavioral flexibility
Aston-Jones, G., Rajkowski, J., & Cohen, J. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00140-7 · Cited by 900
Cited by
Reconsidering anhedonia in depression: Lessons from translational neuroscience
Treadway, M. T., & Zald, D. H. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.06.006 · Cited by 1,579
“…and reward-processing deficits in depression (APA, 2000; Dunlop and Nemeroff, 2007; McCabe et al., 2009; Nutt et al., 2007; Price et al., 2009; Shelton and Tomarken, 2001), and the presence of anhedonic symptoms is a predictor of poor treatment response generally (Spijker et al., 2001).”
BackgroundInfluentialTreadway, M. T., Buckholtz, J. W., Schwartzman, A. N., Lambert, W. E., & Zald, D. H. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006598 · Cited by 769
Treadway, M. T., Bossaller, N. A., Shelton, R. C., & Zald, D. H. (2012) · Journal of Abnormal Psychology · doi:10.1037/a0028813 · Cited by 733
“Moreover, our results are consistent with significant prior evidence that SSRI treatments fail to address symptoms related to motivation and anhedonia in MDD (Nutt et al., 2007; Shelton & Tomarken, 2001).”
Inflammation Effects on Motivation and Motor Activity: Role of Dopamine
Felger, J. C., & Treadway, M. T. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.143 · Cited by 442
Reduced Reward Learning Predicts Outcome in Major Depressive Disorder
Vrieze, E., Pizzagalli, D. A., Demyttenaere, K., Hompes, T., Sienaert, P., de Boer, P., Schmidt, M., & Claes, S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.014 · Cited by 441
Nutt, D., Demyttenaere, K., Janka, Z., Aarre, T., Bourin, M., Canonico, P. L., Carrasco, J. L., & Stahl, S. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106069938 · Cited by 366
McCabe, C., Mishor, Z., Cowen, P. J., & Harmer, C. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.11.001 · Cited by 365
“This is in line with clinical bservations that catecholamine-potentiating agents appear less ffective than SSRIs at reducing distress and negative affect and ave less overall utility, for example, in the management of nxiety disorders (5,35).”
InfluentialWilliams, L. M. (2017) · Depression and Anxiety · doi:10.1002/da.22556 · Cited by 291
Positron emission tomography imaging in depression: a neural systems perspective
Mayberg, H. S. (2003) · Neuroimaging Clinics of North America · doi:10.1016/s1052-5149(03)00104-7 · Cited by 255
Neural correlates of change in major depressive disorder anhedonia following open-label ketamine
Lally, N., Nugent, A. C., Luckenbaugh, D. A., Niciu, M. J., Roiser, J. P., & Zarate, C. A. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114568041 · Cited by 224
Assessing the effects of bupropion SR on mood dimensions of depression
Tomarken, A. J., Dichter, G. S., Freid, C., Addington, S., & Shelton, R. C. (2004) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00306-3 · Cited by 139
Self-citationEfficacy markers in depression
Harmer, C. J., Cowen, P. J., & Goodwin, G. M. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110367722 · Cited by 122
“…on reward processing in humans but clinical observation suggests that while SSRIs are effective at attenuating pervasive negative affect, their ability to improve diminished positive affect by relieving symptoms of low energy, motivation and pleasure is questionable (Shelton and Tomarken, 2001).”
BackgroundResultInfluentialYoung, C. B., Chen, T., Nusslock, R., Keller, J., Schatzberg, A. F., & Menon, V (2016) · Translational Psychiatry · doi:10.1038/tp.2016.80 · Cited by 108
Dunn, B. D., German, R. E., Khazanov, G., Xu, C., Hollon, S. D., & DeRubeis, R. J. (2020) · Clinical Psychological Science · doi:10.1177/2167702619863427 · Cited by 92
Culpepper, L., Muskin, P. R., & Stahl, S. M. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.07.001 · Cited by 77
Tran, P., Skolnick, P., Czobor, P., Huang, N. Y., Bradshaw, M., McKinney, A., & Fava, M. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2011.09.003 · Cited by 81
A dimensional approach to modeling symptoms of neuropsychiatric disorders in the marmoset monkey
Oikonomidis, L., Santangelo, A. M., Shiba, Y., Clarke, F. H., Robbins, T. W., & Roberts, A. C. (2017) · Developmental Neurobiology · doi:10.1002/dneu.22446 · Cited by 54
Saade, Y. M., Nicol, G., Lenze, E. J., Miller, J. P., Yingling, M., Wetherell, J. L., Reynolds, C. F., & Mulsant, B. H. (2019) · Depression and Anxiety · doi:10.1002/da.22964 · Cited by 47
Pringle, A., McCabe, C., Cowen, P., & Harmer, C. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112474523 · Cited by 37
Marutani, T., Yahata, N., Ikeda, Y., Ito, T., Yamamoto, M., Matsuura, M., Matsushima, E., Okubo, Y., Suzuki, H., & Matsuda, T. (2011) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2011.02189.x · Cited by 16
Metadata
- Authors
- Shelton, R. C., & Tomarken, A. J.
- Venue
- Psychiatric Services
- Published
- 2001-11
- Volume
- 52
- Issue
- 11
- Pages
- 1469-1478
- ISSN
- 0022-1597 (ISSN-L)
- 1075-2730
- 1557-9700
- OpenAlex
- W2032542268
- Cited by
- 105
- References
- 23
- FWCI
- 1.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.